Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
Publishing timestamp: 2023-07-27 14:57:29
Summary
Eli Lilly's experimental drug tirzepatide helped patients achieve significant weight loss in two late-stage studies, positioning the company as a strong competitor in the weight loss drug market. The drug resulted in an average weight loss of 26% after extended use or intensive lifestyle changes, further solidifying Eli Lilly's position in the industry.
Sentiment: POSITIVE
Keywords: biotech and pharmaceuticals, biotechnology, breaking news, weight management, business news, business, pharmaceuticals, fda, science, health care industry, obesity, lilly drn, elon musk, clinical trials, novo nordisk a/s,
Source: https://www.cnbc.com/2023/07/27/eli-lilly-obesity-drug-results.html